Skip to main content
Join The Community

Investing, Stocks, Stocks to Buy, Videos

Eli Lilly Stock Could Surge 45% in 2026 as Obesity Drug Sales Explode

By Rick Orford · February 18, 2026

Eli Lilly (NYSE: LLY) is entering 2026 with explosive revenue growth, strong momentum in its powerful obesity drug, and multiple Phase 3 catalysts. With guidance pointing toward $83 billion in revenue and analysts targeting major upside, this healthcare giant could still have significant room to run.

Stock prices used were the market prices of Feb. 13, 2026. The video was published on Feb. 17, 2026. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video.

Watch the latest stock breakdowns on YouTube

New videos on stocks, options income and dividends from Rick Orford. Subscribe so you never miss one.